29.27

2.45% -0.70

Hims Hers Health Inc (HIMS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HIMS? Forum Prognose

Schlusskurs vom Vortag:

$29.97

Offen:

$29.74

24-Stunden-Volumen:

5.63M

Relative Volume:

0.31

Marktkapitalisierung:

$6.83B

Einnahmen:

$2.35B

Nettoeinkommen (Verlust:

$128.37M

KGV:

56.06

EPS:

0.5221

Netto-Cashflow:

$57.42M

1W Leistung:

-1.43%

1M Leistung:

-14.97%

6M Leistung:

+79.36%

1J Leistung:

-39.51%

1-Tages-Spanne:

$28.54

$30.10

1-Wochen-Bereich:

$28.54

$32.29

52-Wochen-Spanne:

$13.74

$65.30

Hims Hers Health Inc Stock (HIMS) Company Profile

Firmenname

Hims Hers Health Inc

Sektor

Healthcare (1082)

Branche

Drug Manufacturers - Specialty & Generic (88)

Telefon

415-851-0195

Adresse

2269 CHESTNUT ST, SAN FRANCISCO

Mitarbeiter

2,442

Twitter

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

HIMS's Discussions on Twitter

Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HIMS Hims Hers Health Inc	29.27	6.99B	2.35B	128.37M	57.42M	0.5221
TAK Takeda Pharmaceutical Co Adr	17.44	55.60B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.7802	43.16B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	36.72	42.81B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	74.03	30.39B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	506.78	21.95B	3.17B	1.29B	1.01B	27.09

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-24	Eingeleitet	JP Morgan	Overweight
2026-03-10	Hochstufung	BofA Securities	Underperform → Neutral
2026-03-10	Hochstufung	Citigroup	Sell → Neutral
2026-03-09	Hochstufung	Needham	Hold → Buy
2026-02-24	Herabstufung	BTIG Research	Buy → Neutral
2026-01-12	Eingeleitet	Evercore ISI	In-line
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-21	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2025-06-23	Herabstufung	Needham	Buy → Hold
2025-06-04	Bestätigt	Needham	Buy
2025-04-29	Herabstufung	TD Cowen	Buy → Hold
2025-02-18	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-01-10	Herabstufung	Citigroup	Neutral → Sell
2025-01-07	Eingeleitet	BTIG Research	Buy
2024-12-17	Eingeleitet	Morgan Stanley	Overweight
2024-11-14	Herabstufung	BofA Securities	Buy → Underperform
2024-08-22	Eingeleitet	Needham	Buy
2024-08-09	Herabstufung	Imperial Capital	Outperform → In-line
2024-05-22	Herabstufung	Citigroup	Buy → Neutral
2024-04-16	Herabstufung	Jefferies	Buy → Hold
2024-04-10	Eingeleitet	Canaccord Genuity	Buy
2024-02-28	Hochstufung	Imperial Capital	In-line → Outperform
2024-02-26	Eingeleitet	Leerink Partners	Market Perform
2023-12-07	Eingeleitet	Imperial Capital	In-line
2023-07-28	Eingeleitet	TD Cowen	Outperform
2023-04-11	Eingeleitet	Robert W. Baird	Neutral
2023-02-09	Hochstufung	Jefferies	Hold → Buy
2022-11-08	Hochstufung	BofA Securities	Neutral → Buy
2022-11-08	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-10-17	Herabstufung	Piper Sandler	Overweight → Neutral
2022-09-07	Eingeleitet	Truist	Hold
2022-07-15	Eingeleitet	SVB Leerink	Underperform
2022-04-14	Eingeleitet	Guggenheim	Buy
2022-04-01	Fortgesetzt	Credit Suisse	Outperform
2022-03-10	Eingeleitet	Deutsche Bank	Hold
2021-12-02	Eingeleitet	Jefferies	Hold
2021-11-11	Hochstufung	Piper Sandler	Neutral → Overweight
2021-07-06	Eingeleitet	BofA Securities	Neutral
2021-05-20	Hochstufung	Credit Suisse	Neutral → Outperform
2021-04-21	Eingeleitet	Truist	Hold
2021-03-09	Eingeleitet	Credit Suisse	Neutral
2021-03-02	Hochstufung	Citigroup	Neutral → Buy
2021-02-17	Eingeleitet	Citigroup	Neutral
2021-02-12	Eingeleitet	Piper Sandler	Neutral
2021-02-08	Eingeleitet	Tigress Financial	Buy

Alle ansehen

Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten

10:05 AM

FTC lawsuit alleges Hims & Hers charged consumers for unwanted prescriptions - Top Class Actions

10:05 AM

Aug 12, 2026

HIMS SHAREHOLDER ALERT: Hims & Hers Health, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire

Aug 12, 2026

A Major Telehealth Company Will Sell Longevity Peptides That Clinical Evidence Has Not Yet Backed - Medical Daily

Aug 12, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Aug 12, 2026

Hims & Hers shared patient health data with Meta, Snap and other advertisers, new class action lawsuit claims - Claim Depot

Aug 12, 2026

NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm - Morningstar

Aug 12, 2026

As Hims prepares for peptides launch, Wall Street cautious on prospects this year - Reuters

Aug 12, 2026

Securities Fraud Investigation Into Hims & Hers Health, - GlobeNewswire

Aug 12, 2026

Investigation launched into Hims & Hers for all... - Pluang

Aug 12, 2026

Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS) - marketscreener.com

Aug 12, 2026

Hims & Hers’ Revenue Beat Came With a Profitability Problem - MarketBeat

Aug 12, 2026

Hims & Hers: The Guidance Raise Doesn't Fix The Margin Problem (NYSE:HIMS) - Seeking Alpha

Aug 12, 2026

Hims & Hers Health (HIMS) Stock Looks Cheap Even With Legal Risk - Yahoo Finance

Aug 12, 2026

Hims & Hers Health: Algorithmic Transformation of Consumer Healthcare - healthcare.digital

Aug 12, 2026

Hims & Hers Q2 Revenue Jumps 38% as International Expansion Accelerates - globalcosmeticsnews.com

Aug 12, 2026

Aug 11, 2026

HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide - TradingView

Aug 11, 2026

Hims & Hers Health, Inc. Signals Aggressive Growth Path - tipranks.com

Aug 11, 2026